Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Accumulated Expenses: 2010-2025

Historic Other Accumulated Expenses for Ironwood Pharmaceuticals (IRWD) over the last 13 years, with Sep 2025 value amounting to $7.5 million.

  • Ironwood Pharmaceuticals' Other Accumulated Expenses fell 4.09% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 4.09%. This contributed to the annual value of $4.4 million for FY2024, which is 28.71% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Other Accumulated Expenses of $7.5 million as of Q3 2025, which was up 44.04% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Other Accumulated Expenses registered a high of $14.3 million during Q3 2023, and its lowest value of $1.9 million during Q1 2021.
  • For the 3-year period, Ironwood Pharmaceuticals' Other Accumulated Expenses averaged around $8.1 million, with its median value being $7.5 million (2025).
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Other Accumulated Expenses plummeted by 55.11% in 2021 and then skyrocketed by 255.92% in 2023.
  • Ironwood Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $3.4 million in 2021, then grew by 4.59% to $3.6 million in 2022, then skyrocketed by 72.14% to $6.2 million in 2023, then fell by 28.71% to $4.4 million in 2024, then dropped by 4.09% to $7.5 million in 2025.
  • Its Other Accumulated Expenses was $7.5 million in Q3 2025, compared to $5.2 million in Q2 2025 and $7.5 million in Q1 2025.